Skip to content
value.today
Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR
$356 Mmarket cap on Oct 23, 2026+118.7% since Jan 2024
Compare
World rank
#14,039
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-105 M
value.today research
Employees
231
As of December 31, 2025
SEC filing

Capricor Therapeutics, Inc. in brief

Capricor Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $356 M on 23 October 2026, which makes it the 14,039th largest listed company in the world and the 2,751st largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $105 M. It employs about 231 people and Linda Marban is its chief executive. Its largest business segments by sales in 2024 were Single reportable segment (100%). Its shares trade under the symbol CAPR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy, a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have devoted substantial resources to the development of our lead product candidate, Deramiocel, a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD, as well as to advancing our exosome-based platform, developing manufacturing capabilities and supporting our research and development activities. Our Biologics License Application for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act target action date of August 22, 2026, for potential approval in the United States. We currently have no products approved for commercial sale. Our ability to generate product revenue and achieve profitability will depend on the successful development, regulatory approval and commercialization of Deramiocel and any other product candidates we may develop. If approved, we intend to commercialize Deramiocel in the United States and may seek commercialization through strategic partners in other select international markets.

From the company's annual report filed with the US SEC: read the report

Capricor Therapeutics, Inc. timeline

4 events, 2001–2023
  1. 2001
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2007
  4. ✎
    Renamed Nile Therapeutics, Inc.
    Formerly Smi Products Inc.
  5. 2013
  6. ✎
    Renamed Capricor Therapeutics, Inc.
    Formerly Nile Therapeutics, Inc..
  7. 2023
  8. 💰
    Record revenue of $25 million
    FY2023, the highest of the 7 years on record.

Events of Capricor Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$390 M$779 M$1.2 B$1.6 B2020202120222023202420252026

World rank over time

▲ up 13,028 places since 2020
2020-01-01: #27104#27,10420202021-01-01: #19248#19,24820212022-01-07: #24681#24,68120222022-12-25: #22276#22,27620222023-07-30: #20979#20,97920232024-01-05: #18960#18,96020242026-03-08: #3643#3,64320262026-08-01: #13280#13,28020262026-10-14: #13623#13,62320262026-10-23: #14076#14,0762026

Rank in USA: #4,755 (Jan 2020) · #3,853 (Jan 2021) · #4,653 (Jan 2022) · #4,377 (Dec 2022) · #4,096 (Jul 2023) · #3,384 (Jan 2024) · #689 (Mar 2026) · #2,694 (Aug 2026) · #2,659 (Oct 2026) · #2,755 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.2×
Free cash flow yield
-20.4%
Net margin
—
Operating margin
—
Return on equity
-34.4%
Liabilities / assets
14.1%
Revenue growth
-11.6%
R&D / revenue
224.4%
Revenue per employee
$0 K
Profit per employee
$-455 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-15M$2MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-8M$1MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-14M$0MFY20Fiscal year ending Dec 2021: revenue $0M, net income $-20M$0MFY21Fiscal year ending Dec 2022: revenue $3M, net income $-29M$3MFY22Fiscal year ending Dec 2023: revenue $25M, net income $-22M$25MFY23Fiscal year ending Dec 2024: revenue $22M, net income $-40M$22MFY24Fiscal year ending Dec 2025: revenue —, net income $-105M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-108M$-105M—
Dec 2024$22M-11.6%$-43M$-40M-181.7%
Dec 2023$25M+887.5%$-24M$-22M-88.5%
Dec 2022$3M+962.5%$-30M$-29M-1138.0%
Dec 2021$0M-22.6%$-21M$-20M-8341.7%
Dec 2020$0M-69.3%$-14M$-14M-4406.5%
Dec 2019$1M-39.5%$-8M$-8M-756.4%
Dec 2018$2M—$-15M$-15M-909.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-70M$3M$-73M$-2.26—
Dec 2024$-40M$1M$-41M$-1.15—
Dec 2023$-26M$1M$-27M$-0.83—
Dec 2022$5M$2M$3M$-1.18—
Dec 2021$-17M$1M$-18M$-0.87—
Dec 2020$-10M$1M$-11M$-0.88—
Dec 2019$-7M$0M$-7M$-2.06—
Dec 2018$-14M$0M$-14M$-0.52—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $11M, net income $-7M$11MDec ’24Three months to Mar 2025: revenue —, net income $-24M—Mar ’25Three months to Jun 2025: revenue —, net income $-26M—Jun ’25Three months to Sep 2025: revenue —, net income $-25M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-30M—Dec ’25Three months to Mar 2026: revenue —, net income $-34M—Mar ’26Three months to Jun 2026: revenue —, net income $-41M—Jun ’26Three months to Sep 2026: revenue —, net income $-43M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-43M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Capricor Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-108 M
Net income
$-105 M

For year ending December-2025

Balance sheet

Total assets
$356 M
Total liabilities
$50 M
Total equity
$306 M

As of December-2025

Top 100 institutional investors in Capricor Therapeutics, Inc.#

As of Sep 30, 2026
158 institutions held 40.2 M shares (about 69.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 36.9%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Capricor Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.4,178,205+33,144 (+0.80%)7.19%$40 MNov 13, 2026
2State Street Corp3,019,025-378,125 (-11.13%)5.19%$29 MNov 12, 2026
3Ra Capital Management, L.P.3,014,183+1,506,339 (+99.90%)5.18%$29 MNov 16, 2026
4Vanguard Capital Management LLC2,303,381+5,707 (+0.25%)3.96%$22 MNov 13, 2026
5D. E. Shaw & Co., Inc.2,141,641+2,017,895 (+1630.67%)3.68%$20 MNov 16, 2026
6Millennium Management LLC1,669,083+1,435,157 (+613.51%)2.87%$16 MNov 16, 2026
7UBS Group AG1,403,356+783,695 (+126.47%)2.41%$13 MNov 10, 2026
8EcoR1 Capital, LLC1,376,580New2.37%$13 MNov 16, 2026
9Longaeva Partners L.P.1,231,841+1,157,795 (+1563.62%)2.12%$12 MNov 16, 2026
10Geode Capital Management, LLC1,137,681-234,605 (-17.10%)1.96%$11 MNov 6, 2026
11Two Sigma Investments, LP946,870New1.63%$9 MNov 16, 2026
12Jones Hill Capital LP892,532+471,781 (+112.13%)1.54%$8 MNov 13, 2026
13Perceptive Advisors LLC850,000New1.46%$8 MNov 16, 2026
14Balyasny Asset Management L.P.812,718+325,882 (+66.94%)1.40%$8 MNov 16, 2026
15Mercer Global Advisors Inc /adv808,610+5,878 (+0.73%)1.39%$8 MNov 16, 2026
16Susquehanna International Group, LLP700,431+690,969 (+7302.57%)1.20%$7 MNov 16, 2026
17Soleus Capital Management, L.P.699,149-62,588 (-8.22%)1.20%$7 MNov 16, 2026
18Goldman Sachs Group Inc697,355-880,776 (-55.81%)1.20%$7 MNov 16, 2026
19Point72 Asset Management, L.P.671,505+576,782 (+608.91%)1.15%$6 MNov 16, 2026
20Boxer Capital Management, LLC642,837-752,319 (-53.92%)1.11%$6 MNov 16, 2026
21Palo Alto Investors LP548,071+318,308 (+138.54%)0.94%$5 MNov 16, 2026
22ADAR1 Capital Management, LLC526,996+436,403 (+481.72%)0.91%$5 MNov 16, 2026
23Vanguard Portfolio Management LLC517,260-118,827 (-18.68%)0.89%$5 MNov 13, 2026
24Northern Trust Corp508,100+4,568 (+0.91%)0.87%$5 MNov 16, 2026
25Jump Financial, LLC480,286+457,250 (+1984.94%)0.83%$5 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Capricor Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26National Bank Of Canada /fi/399,300+399,289 (+3629900.00%)0.69%$4 MNov 16, 2026
27Vanguard Fiduciary Trust Co379,254+6,715 (+1.80%)0.65%$4 MNov 13, 2026
28Morgan Stanley377,740-306,775 (-44.82%)0.65%$4 MNov 13, 2026
29Citigroup Inc360,665+280,542 (+350.14%)0.62%$3 MNov 4, 2026
30Jpmorgan Chase & Co339,771-22,730 (-6.27%)0.58%$3 MNov 12, 2026
31DG Capital Management, LLC279,558-332,037 (-54.29%)0.48%$3 MNov 12, 2026
32Barclays PLC275,957+208,517 (+309.19%)0.47%$3 MNov 6, 2026
33RTW Investments, LP250,0000 (0.00%)0.43%$2 MNov 16, 2026
34Quantinno Capital Management LP248,285+233,444 (+1572.97%)0.43%$2 MNov 13, 2026
35Squarepoint Ops LLC238,892+219,161 (+1110.74%)0.41%$2 MNov 9, 2026
36Ikarian Capital, LLC229,215-375,000 (-62.06%)0.39%$2 MNov 16, 2026
37HBK Sorce Advisory LLC225,256+2,180 (+0.98%)0.39%$2 MNov 6, 2026
38Cantor Fitzgerald, L. P.225,000New0.39%$2 MNov 16, 2026
39Nuveen, LLC210,651-25,961 (-10.97%)0.36%$2 MNov 10, 2026
40Corient Private Wealth LP205,343New0.35%$2 MNov 16, 2026
41Oppenheimer & Co Inc203,781+128,067 (+169.15%)0.35%$2 MOct 26, 2026
42Raymond James Financial Inc200,148+3,292 (+1.67%)0.34%$2 MNov 12, 2026
43Caption Management, LLC175,750+103,750 (+144.10%)0.30%$2 MNov 16, 2026
44Bank of New York Mellon Corp164,260+2,493 (+1.54%)0.28%$2 MNov 5, 2026
45Charles Schwab Investment Management Inc161,010+72 (+0.04%)0.28%$2 MNov 16, 2026
46State Of Wisconsin Investment Board160,896+94,008 (+140.55%)0.28%$2 MNov 16, 2026
47Bank Of America Corp /de/156,174-95,061 (-37.84%)0.27%$1 MNov 16, 2026
48FMR LLC138,986-998,744 (-87.78%)0.24%$1 MNov 10, 2026
49Group One Trading LLC133,714-138,895 (-50.95%)0.23%$1 MNov 10, 2026
50Erste Asset Management GmbH112,000New0.19%$1 MNov 12, 2026
51Swiss National Bank92,9000 (0.00%)0.16%$1 MNov 12, 2026
52Rock Springs Capital Management LP87,007+12,559 (+16.87%)0.15%$1 MNov 16, 2026
53Trexquant Investment LP81,851-115,942 (-58.62%)0.14%$1 MNov 16, 2026
54Deeter Investments LLP80,898New0.14%$1 MNov 16, 2026
55Algert Global LLC79,200+48,590 (+158.74%)0.14%$1 MNov 17, 2026
56Black Diamond Financial, LLC79,0770 (0.00%)0.14%$1 MOct 26, 2026
57LPL Financial LLC77,853+50,476 (+184.37%)0.13%$1 MNov 6, 2026
58Rafferty Asset Management, LLC77,244+16,871 (+27.94%)0.13%$1 MNov 13, 2026
59Boothbay Fund Management, LLC75,405-117,557 (-60.92%)0.13%$1 MNov 16, 2026
60UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC75,200+770 (+1.03%)0.13%$1 MNov 16, 2026
61Alliancebernstein L.P.69,500+12,200 (+21.29%)0.12%$1 MNov 16, 2026
62Commonwealth Equity Services, LLC67,402+40,627 (+151.73%)0.12%$1 MNov 2, 2026
63Rhumbline Advisers65,395-2,486 (-3.66%)0.11%$1 MNov 10, 2026
64Citadel Advisors LLC62,600-751,844 (-92.31%)0.11%$1 MNov 16, 2026
65Osaic Holdings, Inc.61,529+41,195 (+202.59%)0.11%$1 MNov 12, 2026
66Quadrature Capital Ltd60,246New0.10%$1 MNov 13, 2026
67Foundations Investment Advisors, LLC60,013+3 (0.00%)0.10%$1 MNov 12, 2026
68Axq Capital, LP58,575New0.10%$1 MNov 12, 2026
69California State Teachers Retirement System54,625-8,850 (-13.94%)0.09%$1 MNov 13, 2026
70Deutsche Bank AG\54,214-3,365 (-5.84%)0.09%$1 MNov 6, 2026
71Exome Asset Management LLC51,531New0.09%$0 MNov 16, 2026
72Creative Planning48,486+29,899 (+160.86%)0.08%$0 MNov 2, 2026
73Gsa Capital Partners LLP46,182New0.08%$0 MNov 16, 2026
74Price T Rowe Associates Inc /MD/44,7480 (0.00%)0.08%$0 MNov 16, 2026
75Simplex Trading, LLC42,344New0.07%$0 MNov 4, 2026
76Lighthouse Investment Partners, LLC40,000New0.07%$0 MNov 16, 2026
77Legal & General Group Plc38,5130 (0.00%)0.07%$0 MNov 16, 2026
78Entropy Technologies, LP36,202New0.06%$0 MNov 13, 2026
79Dauntless Investment Group, LLC35,000+34,999 (+3499900.00%)0.06%$0 MNov 16, 2026
80VANGUARD ASSET MANAGEMENT, Ltd32,2650 (0.00%)0.06%$0 MNov 13, 2026
81MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.31,658-121 (-0.38%)0.05%$0 MNov 16, 2026
82Shay Capital LLC30,000New0.05%$0 MNov 16, 2026
83Profund Advisors LLC27,231-3,251 (-10.67%)0.05%$0 MOct 29, 2026
84Invesco Ltd.27,121-2,431 (-8.23%)0.05%$0 MNov 12, 2026
85SBI Securities Co., Ltd.26,310+23,495 (+834.64%)0.05%$0 MOct 22, 2026
86Capital Fund Management S.A.25,911New0.04%$0 MNov 13, 2026
87MetLife Investment Management, LLC25,767-5,613 (-17.89%)0.04%$0 MNov 16, 2026
88Connective Capital Management, LLC25,552New0.04%$0 MNov 16, 2026
89Caitong International Asset Management Co., Ltd22,754New0.04%$0 MOct 29, 2026
90Janus Henderson Group Ltd.22,600—0.04%$0 MNov 16, 2026
91Cerity Partners LLC21,304New0.04%$0 MNov 13, 2026
92Tower Research Capital LLC (TRC)20,195+17,342 (+607.85%)0.03%$0 MNov 16, 2026
93VestGen Advisors, LLC20,164New0.03%$0 MOct 27, 2026
94Sculptor Capital LP20,000New0.03%$0 MNov 13, 2026
95Vanguard Global Advisers, LLC19,952-8,600 (-30.12%)0.03%$0 MNov 13, 2026
96Federated Hermes, Inc.19,580New0.03%$0 MNov 12, 2026
97New York State Common Retirement Fund18,600-300 (-1.59%)0.03%$0 MNov 17, 2026
98BNP Paribas Financial Markets17,403+6,824 (+64.51%)0.03%$0 MNov 12, 2026
99Russell Investments Group, Ltd.17,326+3,036 (+21.25%)0.03%$0 MNov 6, 2026
100Wells Fargo & Company/mn16,444-36,744 (-69.08%)0.03%$0 MNov 16, 2026

All 158 institutional investors, with who bought and sold →

Mutual funds holding Capricor Therapeutics, Inc.#

113 funds in 2 countries hold shares worth $232 M (about 10.2% of the company). Since their previous reports 75 added shares and 27 sold, buying $41 M net. By country: USA 112 ($231 M), Sweden 1 ($1 M).
Mutual funds holding Capricor Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.2.18 M$52 M2.2%0.49%+86%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.66 M$40 M1.7%<0.01%+13%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.40 M$34 M1.4%0.04%+32%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.591,508$14 M0.59%0.01%+15%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors496,401$12 M0.50%0.08%+39%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC334,200$10 M0.33%0.19%+6.2%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC238,101$7 M0.24%0.02%−1.1%May 31, 2026
🇺🇸 Select Pharmaceuticals PortfolioFidelity Management & Research Company LLC231,300$7 M0.23%0.46%−41%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.223,876$7 M0.22%0.04%+17%May 31, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC190,170$6 M0.19%<0.01%no changeMay 31, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC87,370$3 M0.09%0.63%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC86,770$3 M0.09%<0.01%+2.0%May 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.85,131$3 M0.09%0.14%+156%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC100,532$2 M0.10%0.04%+42%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC587,905$2 M0.59%<0.01%+36%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC69,945$2 M0.07%<0.01%+2.7%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors66,615$2 M0.07%<0.01%+2.5%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC58,475$1 M0.06%0.04%+29%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC54,655$1 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.40,983$1 M0.04%0.07%+16%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC50,388$1 M0.05%0.08%+52%Jun 30, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.48,562$1 M0.05%0.10%−6.7%Jun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC35,895$1 M0.04%0.02%−1.2%May 29, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC34,872$1 M0.03%<0.01%+8.2%May 31, 2026
🇸🇪 SEB Nordamerikafond SmåbolagSEB Funds AB41,567$1 M0.04%0.36%+163%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation38,100$1 M0.04%0.04%+45%Jun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC31,880$1 M0.03%0.04%+52%Jun 30, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC20,771$1 M0.02%0.38%—Apr 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.27,170$1 M0.03%0.04%+36%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.25,820$1 M0.03%<0.01%−4.2%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.25,137$1 M0.03%<0.01%+13%Jun 30, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.19,594$1 M0.02%0.07%newMay 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company17,130$1 M0.02%0.04%+8.0%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.130,634$1 M0.13%<0.01%+36%Jul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds20,496$0 M0.02%0.06%+17%Jun 30, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation19,492$0 M0.02%0.05%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC19,310$0 M0.02%0.02%+45%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC15,068$0 M0.02%<0.01%+11%May 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.18,000$0 M0.02%0.01%+21%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC17,789$0 M0.02%0.04%+34%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC110,633$0 M0.11%<0.01%+207%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC16,462$0 M0.02%0.04%+21%Jun 30, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC16,452$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC15,444$0 M0.02%0.04%+36%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.14,045$0 M0.01%0.08%−2.8%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors12,886$0 M0.01%<0.01%−0.8%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.10,262$0 M0.01%0.03%−48%May 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS11,904$0 M0.01%0.04%+39%Jun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC73,804$0 M0.07%0.06%+10.0%Jul 31, 2026
🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation10,837$0 M0.01%0.11%−5.3%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC10,763$0 M0.01%0.04%+36%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC66,406$0 M0.07%<0.01%+27%Jul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION7,200$0 M<0.01%0.02%no changeMay 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors8,554$0 M<0.01%<0.01%−24%Jun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC6,766$0 M<0.01%0.12%—Mar 31, 2026
🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY6,778$0 M<0.01%0.06%newMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC8,300$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC8,294$0 M<0.01%0.03%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.8,287$0 M<0.01%0.04%+36%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.8,203$0 M<0.01%0.04%+60%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,894$0 M<0.01%0.04%+34%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC7,253$0 M<0.01%0.04%+36%Jun 30, 2026
🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC7,133$0 M<0.01%0.05%−5.0%Jun 30, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC6,766$0 M<0.01%0.04%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,519$0 M<0.01%0.04%+38%Jun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.40,091$0 M0.04%<0.01%−36%Jul 31, 2026
🇺🇸 Putnam Dynamic Asset Allocation Growth FundFranklin Advisers, Inc.6,278$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,881$0 M<0.01%0.04%+37%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.30,264$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC4,759$0 M<0.01%0.08%+47%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC28,172$0 M0.03%<0.01%+16%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,531$0 M<0.01%<0.01%+20%May 31, 2026
🇺🇸 Putnam Dynamic Asset Allocation Balanced FundFranklin Advisers, Inc.4,358$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC4,295$0 M<0.01%0.04%+47%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC4,242$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC25,706$0 M0.03%<0.01%+36%Jul 31, 2026
🇺🇸 iShares MSCI World Small-Cap ETFBlackRock Fund Advisors2,986$0 M<0.01%0.01%newMay 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,638$0 M<0.01%0.01%+18%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,601$0 M<0.01%0.04%+33%Jun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC21,985$0 M0.02%<0.01%−2.1%Jul 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC3,401$0 M<0.01%0.06%+12%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC18,822$0 M0.02%<0.01%+17%Jul 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,051$0 M<0.01%0.03%+23%May 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC2,322$0 M<0.01%<0.01%−23%Jun 30, 2026
🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC2,290$0 M<0.01%0.04%−9.1%Jun 30, 2026
🇺🇸 JPMorgan BetaBuilders U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc.14,178$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,622$0 M<0.01%0.01%−32%May 31, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC1,604$0 M<0.01%0.02%−33%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,885$0 M<0.01%0.02%+33%Jun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,350$0 M<0.01%<0.01%−4.9%May 31, 2026
🇺🇸 Multimanager Aggressive Equity PortfolioEquitable Investment Management Group, LLC1,600$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC9,500$0 M<0.01%<0.01%+36%Jul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,358$0 M<0.01%<0.01%+31%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC1,034$0 M<0.01%<0.01%+30%May 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC7,732$0 M<0.01%<0.01%+11%Jul 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,142$0 M<0.01%<0.01%+3.9%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.6,046$0 M<0.01%<0.01%+8.1%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,983$0 M<0.01%<0.01%+42%Jul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC886$0 M<0.01%<0.01%+23%Jun 30, 2026
🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC886$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Capricor Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$6.8 M
13 sales, 3 insiders
Net, 12 months
-$6.8 M
open market only
Insiders on file
22
since
$15.0 M-$3.4 M$0Sep 2024: bought $15.0 M (1 trades), sold $0 (0 trades)Sep 24Mar 2026: bought $0 (0 trades), sold $3.4 M (3 trades)MarApr 2026: bought $0 (0 trades), sold $1.9 M (2 trades)AprMay 2026: bought $0 (0 trades), sold $793 K (2 trades)MayJun 2026: bought $0 (0 trades), sold $759 K (6 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Capricor Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Karen KrasneyEVP, GENERAL COUNSELOption exercise+24,100$3.180$77 K54,647Form 4
filed Anthony BergmannCHIEF FINANCIAL OFFICEROption exercise+24,100$3.180$77 K35,323Form 4
filed Anthony BergmannCHIEF FINANCIAL OFFICERSell10b5-1 plan-24,100$30.38—11,223Form 4
filed Karen KrasneyEVP, GENERAL COUNSELSell10b5-1 plan-24,100$30.38$732 K30,547Form 4
filed Karen KrasneyEVP, GENERAL COUNSELOption exercise+400$3.180$1 K30,947Form 4
filed Anthony BergmannCHIEF FINANCIAL OFFICEROption exercise+400$3.180$1 K11,623Form 4
filed Karen KrasneyEVP, GENERAL COUNSELSell10b5-1 plan-400$30.00$12 K30,547Form 4
filed Anthony BergmannCHIEF FINANCIAL OFFICERSell10b5-1 plan-400$30.00—11,223Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Capricor Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
18.8 M
32.7% of shares · 7.38 days to cover
Buybacks, Q4 2019
$0M
Q4 2019
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Capricor Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2019Q4 2019$0M
Q3 2019Q3 2019$0M
Q4 2018Q4 2019$0M
Q3 2018Q3 2019$0M

Trading halts

  • 2026-07-29 10:55 UTC, code T3, resumed 11:05 UTC
  • 2025-12-03 15:17 UTC, code LUDP, resumed 15:22 UTC
  • 2025-12-03 15:07 UTC, code LUDP, resumed 15:17 UTC
  • 2025-12-03 14:44 UTC, code LUDP, resumed 15:04 UTC
  • 2025-12-03 14:36 UTC, code LUDP, resumed 14:41 UTC

Fails to deliver

  • : 8,926 shares at $6.13
  • : 2,949 shares at $6.71
  • : 233 shares at $6.88
  • : 2,869 shares at $7.47
  • : 34,495 shares at $8.10

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Capricor Therapeutics, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 23, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-20.4%Free cash flow is -20.4% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.26 vs -1.15Diluted EPS -2.26 in fiscal 2025 against -1.15 the year before (report's currency).
    • ✗Net income higher than five years earlier-$105 M-$105 M in fiscal 2025 against -$14 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$105 MNet income -$105 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-46.6%-46.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities9.0×Current ratio 9.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year32.0%Diluted shares up 32.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Capricor Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Capricor Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue022252.60.20.31.01.72.74.0
Research and development84503622148.55.1121116
General and administrative2415r13107.65.53.64.94.84.9
Operating expenses10865r493221148.7171621
Operating income−108−43r−24−30−21−14−7.7−15−13−17
Interest and finance income6.32.21.70.50.10.00.10.10.00.0
Interest expense and finance costs3.00—————00.40.3
Other non-operating income (expense)3.12.11.80.70.90.00.10.115−1.8
Income before tax−105−40————————
Income tax0.00.0————————
Net income including minority interests−105−40−22−29−20−14————
Net income attributable to shareholders−105−40−22−29−20−14−7.6−152.4−19
Earnings per share, basic-2.26-1.15-0.83-1.18-0.87-0.88-2.06-5.17r0.10-1.01
Earnings per share, diluted-2.26-1.15-0.83-1.18-0.87-0.88-2.06-0.520.09-1.01
Shares, weighted average (basic)4635272523163.72.9r2319
Shares, weighted average (diluted)4635272523163.72.9r2719
Balance sheet
Cash and cash equivalents28811159.635333.94.36.13.2
Short-term investments3014025320—6.03.08.013
Other current assets4.8r1.51.00.91.21.00.60.70.50.3
Current assets32316351433634118.51618
Property, plant and equipment185.65.64.61.80.90.40.60.40.4
Right-of-use (leased) assets141.32.12.32.80————
Other intangible assets————00.00.00.00.10.1
Total assets35617059504135119.21619
Accounts payable1.73.3r6.3r4.83.12.7r0.9r1.11.53.0
Current liabilities362131244.13.00.91.31.74.9
Lease liabilities (non-current)140.61.51.92.50————
Non-current liabilities144.04.9155.83.43.43.43.418
Total liabilities5025363810.06.44.34.65.023
Retained earnings−305−200−159−137−108−88−74−67−52−54
Shareholders' equity306145231231286.84.611−4.0
Total liabilities and equity35617059504135119.21619
Shares outstanding5746312524215.23.1r2621
Cash-flow statement
Depreciation and amortization1.91.41.10.50.20.10.20.20.10.1
Share-based compensation179.87.44.53.02.00.71.71.72.0
Cash from operating activities−70−40−264.9−17−10−6.8−14−14−14r
Capital expenditure−2.9−1.2−1.3−2.0−1.2−0.50−0.3−0.0−0.2
Cash from investing activities97−1165.1−35−1.25.4−3.04.75.0−5.2
Debt issued———————00.54.8
Shares issued237152264.820279.26.71114
Shares bought back—————0−0.00——
Cash from financing activities249153264.920339.26.91219
Change in cash—————————−2.4
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Capricor Therapeutics, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Single reportable segment$22 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Executive pay at Capricor Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.5 M
Linda Marbán
Other top executives, average
$1.5 M
the CEO earned 2.4× this
$100 invested is now
$748
Capricor Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Linda Marbán$3.5 M$7.2 M$1.5 M$748
2024Linda Marban$1.5 M$5.1 M$900 K$358
2023Linda Marban$774 K$1.2 M$741 K$127

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Capricor Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · New debt 1 · Shareholder vote 2 · Results announced 10

Capricor Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Capricor Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2017$4 MPrivate placement after listing$2 to $10 million4equitySEC
Feb 2015$7 MPrivate placement after listing$2 to $10 million8equitySEC
Jan 2015$10 MPrivate placement after listing$10 to $50 million39equitySEC
Nov 2013$26 MPrivate placement after listing$10 to $50 million34equitySEC
Jun 2011$3 MNo. 2$2 to $10 million6equity, optionsSEC
Jul 2009$2 MNo. 1$2 to $10 million24equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Capricor Therapeutics, Inc.#

$110 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues.

Lobbying, 2026
$110 K
#1,156 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2026
2026 so far
$110 K
  • Health Issues1 report

Lobbying firms hired in 2026

CHECKMATE GOVERNMENT RELATIONS $110 K

Capricor Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$110 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Capricor Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Capricor Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2021 for 2 positions, at a median wage of $97 K a year.

Certified, FY2021
2
#1,622 among companies on value.today
Worker positions
2
Median wage offered
$97 K
a year, full-time
Applications filed
2
Capricor Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
Clinical Trial ManagerNatural Sciences Managers1$128 K
Research AssociateMolecular and Cellular Biologists1$67 K

Where: West Hollywood, CA 1 · Beverly Hills, CA 1

Capricor Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202122$97 K2
FY202011$75 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Capricor Therapeutics, Inc.

How Capricor Therapeutics, Inc. compares in Biotechnology

  • Market cap$356 M · higher than 54% of 726
  • Revenue$0 M · higher than 0% of 647
  • Revenue growth-11.6% · higher than 33% of 438
  • Price / book1.2× · lower than 76% of 534
  • FCF yield-20.4% · higher than 44% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Capricor Therapeutics, Inc.🇺🇸$356 M——-11.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 23, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing, SEC annual report, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Capricor Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Capricor Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Capricor Therapeutics, Inc.? Suggest a correction